Business Context and Reporting Period
This Form 8-K is a current report filed by Hemispherx Biopharma, Inc. (not AIM Immunotech Inc.) on December 22, 2010. The filing addresses Item 5.02 regarding compensatory arrangements for certain officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation details:
- 2010 Performance Bonuses: Approved for payment in 2011 based on 2010 performance.
- William A. Carter (Chairman & CEO): $200,000 bonus (25% of base compensation).
- Thomas K. Equels (Executive Vice Chairman): $100,000 bonus (25% of base compensation).
- Charles Bernhardt (CFO): $50,000 bonus (25% of base compensation).
- David Strayer (Medical Director): $48,737 bonus (20% of base compensation).
- Wayne Springate (V.P. of Operations): $36,300 bonus (20% of base compensation).
- Russel Landers (V.P. of Process and Quality Assurance): $43,076 bonus (20% of base compensation).
- Stock Options: William A. Carter received 10-year options to purchase 73,728 shares at an exercise price of $2.71 per share, replacing expired options.
Material Changes
The filing reports the approval of specific cash bonuses and the issuance of replacement stock options for the CEO. No material changes to financial performance or corporate structure are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, outlook, or discussion of risks and contingencies. The compensation decisions were based on the analysis of "Achievement of Job Description and Attainment of Company-Wide Goals" documents.
Investor Verification Checklist
- Verify the total cash outflow for the approved 2010 bonuses ($478,113 total) in the upcoming 2011 financial statements.
- Confirm the dilution impact of the 73,728 replacement options issued to the CEO.
- Review the 2009 Equity Incentive Plan to ensure the replacement options comply with plan limits.
- Note the discrepancy between the requested company name (AIM Immunotech Inc.) and the actual registrant (Hemispherx Biopharma, Inc.).